bdtx-1535
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2022 (NCT05256290)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06072586 | Early Phase 1 (Phase 1) | Oct 18, 2023 | Barrow Neurological Institute, Ivy Brain Tumor Center, University of Arizona |
| NCT05256290 | Phase 1 | Mar 31, 2022 | Black Diamond Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Barrow Neurological Institute | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Black Diamond Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Ivy Brain Tumor Center | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Arizona | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1